Ερευνητικό υλικό ΕΚΠΑ

Treating patients with ALK-rearranged non-small-cell lung cancer:
mechanisms of resistance and strategies to overcome it

Αγγλικά

Anaplastic lymphoma kinase (ALK) rearrangement is detected in 3-7% of
patients with non-small-cell lung cancer. Crizotinib is an ALK
inhibitor, which was approved in 2011 for the treatment of ALK-positive
lung cancer. Despite the initial enthusiasm, most of the patients
develop resistance within the first year of treatment. The main
mechanisms are secondary mutations and bypass track activation.
Moreover, crizotinib has low penetration into the central nervous
system. The need to overcome these limitations has led to the
development of second-generation inhibitors that have better
effectiveness against crizotinib-resistant mutations and brain
metastases. Ceritinib and alectinib are the only approved drugs of this
group. Many ongoing trials try to define the most appropriate agent for
the treatment of ALK-positive lung cancer depending on the responsible
mechanism. This review focuses on the current data regarding the
potential mechanisms of resistance to ALK inhibitors and the strategies
to overcome it.

2017

Drizou, M.
Kotteas, E. A.
Syrigos, N.

Clinical and Translational Oncology

SPRINGER INTERNATIONAL PUBLISHING AG

19

6

658-666

ALK rearrangement; ALK-positive NSCLC; Crizotinib; Ceritinib; Alectinib;
Resistance mechanism

https://doi.org/10.1007/s12094-016-1605-y

10.1007/s12094-016-1605-y

https://pergamos.lib.uoa.gr/uoa/dl/object/3175277